Navigation Links
Scientists Use Live Bacteria to Fight HIV

MOUNTAIN VIEW, Calif., July 18, 2011 /PRNewswire/ -- Scientists at Osel Inc. and the National Cancer Institute (NCI) have developed a new way to prevent HIV infection by genetically enhancing the ability of naturally occurring vaginal bacteria to block viral transmission. Bioengineered bacteria introduced into the vaginal cavity of macaques—a commonly used experimental primate—reduced the transmission of simian HIV (SHIV) by nearly two thirds.

The novel approach takes advantage of lactobacilli, which are beneficial bacteria that play an important role in vaginal health and help protect women against a variety of sexually transmitted infections. The Osel team engineered the common strain Lactobacillus jensenii to pump out therapeutic quantities of the HIV inhibitor cyanovirin-N, which is a protein originally discovered by NCI scientists screening natural substances for antiviral activity.

In a study just published online in advance of publication in the Nature journal Mucosal Immunology, the team showed that vaginal administration of Lactobacillus expressing CV-N to rhesus macaques could reduce the transmission of SHIV (a virus developed for research that combines critical components of HIV with the ability to infect monkeys) by 63 percent after repeated challenges with virus. A reduction in the viral load was also seen in infected macaques that received the Lactobacillus product, called MucoCept.

"We were excited to see this reduced rate of transmission in the macaque model," said Dr. Laurel Lagenaur, the leader of the Osel team. "Because this Lactobacillus strain is likely to colonize women at a higher rate than macaques, we could see an even bigger reduction in the rate of HIV infection when this product is tested in women. The lactobacilli themselves are also beneficial to vaginal health."

The scientists believe their approach could provide an affordable and durable method for reducing the continuing worldwide epidemic of HIV, which currently infects more than two million people every year. A major advantage of the novel approach of a live bioshield such as MucoCept is that it would provide sustained protection; women would not need to apply it frequently or immediately before sexual intercourse.

"This approach has potential as a novel 'natural' approach to prevent HIV," said Dr. Salim S. Abdool Karim of Centre for the AIDS Programme of Research In South Africa (CAPRISA) at the University of KwaZulu-Natal, who co-led a study establishing proof-of-concept for microbicides using tenofovir gel. "Data in women are eagerly awaited." Dr. Karim was not involved in the current study.

"It's exciting to be working on a prevention for HIV that people could actually afford," said Dr. Dean H. Hamer, chief of the Gene Structure and Regulation Section at the NCI and senior author of the study. "While there is much interest in the recent results with PrEP [pre-exposure prophylaxis], it's important to realize that the cost of the required antiretroviral drugs is prohibitive in the real world."

The engineered lactobacilli in MucoCept constitute an ideal microbicide because the organisms naturally colonize the vagina—unlike the strains found in dairy products or food supplements—and they continuously produce the HIV inhibitor. Upon administration of MucoCept as a vaginal suppository, these bacteria can take up residence and potentially protect the user for weeks at a time.

The Osel group is hoping to start human trials of MucoCept within the next several years following completion of product development and safety testing.

These studies were funded by the National Institutes of Health, under federal grants from NIAID and DMID.  The MucoCept HIV project has also been supported by CONRAD-GMP, IPM, USAID, and the Bill and Melinda Gates Foundation.

REFERENCE: Mucosal Immunology; Advanced Online Publication July 6, 2011

About Osel, Inc.

Osel Inc. is a biopharmaceutical company with a proprietary technology platform to develop next-generation probiotics as pharmaceutical products. In addition to MucoCept, Osel is developing an unmodified Lactobacillus crispatus product, LACTIN-V, as a natural antimicrobial-sparing intervention to prevent several common urogenital infections in women, including recurrent urinary tract infections (RUTI) and bacterial vaginosis. LACTIN-V was recently shown to reduce the rate of recurrent urinary tract infection in women by about one-half (Stapleton et al., Clin Infect Dis. 52:1212-1217, May 2011), which compares favorably to antimicrobial prophylaxis, the current standard of care for RUTI. MIYA-BM, containing the novel probiotic bacterium, Clostridium butyricum MIYAIRI 588, is an oral product in clinical development for the prevention of antimicrobial-associated diarrhea and Clostridium difficile infection. For further information, visit

Media Contact
Dr. Laurel Lagenaur—Telephone: 650-964-1420—e-mail:

SOURCE Osel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date
2. MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients
3. Online Career Service to Hold Worlds First Virtual Job Summit for Postgraduate Life Scientists
4. Fisher Center Scientists Show That Anti-Inflammatory Drugs Reduce Effectiveness of SSRI Antidepressants
5. Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando
6. Saint Louis U Scientists Partner on Malaria Research
7. Baltimore to Host Largest Gathering of Cystic Fibrosis Scientists and Clinicians in the World
8. St. Jude Childrens Research Hospital Doctors and Scientists Team up to Fight Childhood Cancer
9. Nigerian Association of Pharmacists and Pharmaceutical Scientists in America (NAPPSA) Announces Prime Vendor Agreement with H. D. Smith
10. Hovione Scientists Bring PAT and Inhalation Expertise to USP
11. Cambridge Scientists Archive 500,000th Crystal Structure
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... most successful and prominent nonprofit healthcare organizations in the country. They have overseen ... various organizations, and helped advance the healthcare industry as a whole through their ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
Breaking Medicine News(10 mins):